Dasabuvir: a new direct antiviral agent for the treatment of hepatitis C

Trivella, Juan; Gutiérrez, Julio; Martin, Paul

doi:10.1517/14656566.2015.1012493

Cited by 24 publications

(20 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Dasabuvir (previously known as ABT-333) is an inhibitor of the hepatitis C virus (HCV) and approved for use in combination with ombitasvir/paritaprevir/ritonavir for the treatment of chronic HCV infection [37,38]. In the HCV subgenomic replicon system, dasabuvir inhibits genotype 1a and 1b replicons with EC 50 values of 7.7 and 1.8 nM, respectively [30].…”

Section: None Of the Pdb Non-nucleoside Co-crystalized With Flavivirumentioning

confidence: 99%

FDA-Approved Drugs Efavirenz, Tipranavir, and Dasabuvir Inhibit Replication of Multiple Flaviviruses in Vero Cells

et al. 2020

View full text Add to dashboard Cite

Vector-borne flaviviruses (VBFs) affect human health worldwide, but no approved drugs are available specifically to treat VBF-associated infections. Here, we performed in silico screening of a library of U.S. Food and Drug Administration-approved antiviral drugs for their interaction with Zika virus proteins. Twelve hit drugs were identified by the docking experiments and tested in cell-based antiviral assay systems. Efavirenz, tipranavir, and dasabuvir at micromolar concentrations were identified to inhibit all VBFs tested; i.e., two representatives of mosquito-borne flaviviruses (Zika and West Nile viruses) and one representative of flaviviruses transmitted by ticks (tick-borne encephalitis virus). The results warrant further research into these drugs, either individually or in combination, as possible pan-flavivirus inhibitors.

show abstract

Section: None Of the Pdb Non-nucleoside Co-crystalized With Flavivirumentioning

confidence: 99%

FDA-Approved Drugs Efavirenz, Tipranavir, and Dasabuvir Inhibit Replication of Multiple Flaviviruses in Vero Cells

et al. 2020

View full text Add to dashboard Cite

show abstract

“… 21 50–52 Dasabuvir has no activity against G4, however. 53 The combination of paritaprevir/r/ombitasvir with RBV for G4 HCV has been studied in the PEARL-1 trial. 54 There were a good number of patients including 135 in total, making it the largest DAA study in G4 HCV.…”

Section: Ifn-free Daa Regimensmentioning

confidence: 99%

Management of hepatitis C genotype 4 in the directly acting antivirals era

Hathorn

Elsharkawy

2016

BMJ Open Gastroenterol

View full text Add to dashboard Cite

Genotype 4 chronic hepatitis C (G4 HCV) accounts for 13% of worldwide HCV infections; with 10 million people infected with the virus across the world. Up to the end of 2013, the only treatment option for G4 HCV was treatment with pegylated interferon and ribavirin for 24–48 weeks. Since late 2013, treatment of G4 HCV has been transformed by the licensing of many directly acting antiviral agents (DAA). It is an exciting time to be involved in the management of HCV generally and G4 particularly. Interferon-free DAA regimens are now a reality for G4 HCV. This review will highlight these developments and discuss the data behind the use of these drugs. It will also highlight future regimens that are likely to be available over the coming years.

show abstract

“…Dasabuvir was developed to treat GT-1-infected patients while is inactive toward GT-2, GT-3, and GT-4 infection. Dasabuvir is well tolerated, and the main adverse events recorded, when in combination with other DAAs, were mild such as headache and fatigue [106,107].…”

Section: Dasabuvirmentioning

confidence: 99%

New Perspective in HCV Clinical and Economical Management of the Current and Future Therapies

Pierimarchi¹,

Nicotera²,

Sferrazza³

et al. 2015

Recent Advances in Liver Diseases and Surgery

View full text Add to dashboard Cite

Hepatitis C virus HCV is a progressive disease that infects more than million individuals worldwide and is associated with persistence of viral replication and ongoing necroinflammation and fibrosis. To date % of patients chronically infected with HCV progress to cirrhosis. Epidemiological studies demonstrate that the incidence of HCV is not well known, because acute infection is generally asymptomatic. The global prevalence is about . % and there is a large degree of geographic variability. "efore the , the gold standard of therapy for the treatment of chronic hepatitis C CHC was based on the combination of pegylated Interferon peg-IFN and Ribavirin R"V . However, several aspects related to safety profile limited their use in clinical practice. In the recent years, thanks to basic research on HCV structure and replicative cycle, it has been possible to develop direct acting antiviral drugs that have dramatically increased the viral clearance rate. Specifically, the advent of the triple therapy employing direct acting antivirals has dramatically increased the viral clearance rate, from less than %, with the initial regimen of IFN monotherapy, to more than % with the current therapy. Even though new medications for hepatitis C are effective disease modifiers and have the potential, in a long term perspective, to eradicate the pathology, the cost of new treatments are unlikely to be sustainable for the NHSs. The evidence documenting the effectiveness and tolerability of the new therapies for HCV and several pharmacoeconomic analysis, shows that despite the cost, the new treatments can be considered cost-effective in the long period. However, the health care systems are unable to compensate the height financial resources immediately needed for treating patients with the long terms savings that will be obtained from the eradication of HCV. Indeed, new pharmaceutical policy and a global commitment is required to improve strategies of treatment and price negotiation with pharmaceutical companies to move from a theoretical cost-effectiveness approach to a practical costsustainable reality.

show abstract

Dasabuvir: a new direct antiviral agent for the treatment of hepatitis C

Cited by 24 publications

References 32 publications

FDA-Approved Drugs Efavirenz, Tipranavir, and Dasabuvir Inhibit Replication of Multiple Flaviviruses in Vero Cells

FDA-Approved Drugs Efavirenz, Tipranavir, and Dasabuvir Inhibit Replication of Multiple Flaviviruses in Vero Cells

Management of hepatitis C genotype 4 in the directly acting antivirals era

New Perspective in HCV Clinical and Economical Management of the Current and Future Therapies

Contact Info

Product

Resources

About